This centralized approachknown as the volume-based procurement policyaims to reduce drug prices, improve efficiency, and ensure consistent quality across the country
If you find one site works better for you, feel free to follow your instincts
[DOI] [PubMed] [Google Scholar] Siwek M, Sowa-Kuma M, Dudek D, Stycze K, Szewczyk B, Kotarska K, Misztakk P, Pilc A, Wolak M, Nowak G
The ADA 2026 Standards of Care now recommend GLP-1 receptor agonists with demonstrated cardiovascular benefit for patients with type 2 diabetes and established ASCVD, multiple cardiovascular risk factors, or chronic kidney disease, and note that combination with SGLT2 inhibitors may provide additive benefit
A thorough medical evaluation is essential before starting any GLP-1 therapy, whether branded or compounded